Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.
Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.